Jacobs Levy Equity Management
YMAB

Jacobs Levy Equity Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Jacobs Levy Equity Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-142,641
Closed -$643K – 1137
2025
Q2 		$643K Sell
142,641
-94,870
-40% -$426K ﹤0.01% 833
2025
Q1 		$1.05M Buy
237,511
+87,830
+59% +$510K ﹤0.01% 800
2024
Q4 		$1.17M Hold
149,681
– – ﹤0.01% 692
2024
Q3 		$1.97M Hold
149,681
– – 0.01% 607
2024
Q2 		$1.81M Sell
149,681
-4,335
-3% -$58.5K 0.01% 622
2024
Q1 		$2.5M Sell
154,016
-98,904
-39% -$1.33M 0.01% 559
2023
Q4 		$1.72M Sell
252,920
-277,519
-52% -$1.61M 0.01% 626
2023
Q3 		$2.89M Sell
530,439
-34,092
-6% -$199K 0.02% 497
2023
Q2 		$3.83M Buy
564,531
+240,634
+74% +$1.8M 0.02% 455
2023
Q1 		$1.62M Buy
+323,897
New +$1.32M 0.01% 610

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jacobs Levy Equity Management's YMAB Position: Q3 2025 in Review

Jacobs Levy Equity Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 142,641 shares — an estimated $643K sold.

Jacobs Levy Equity Management first reported a position in YMAB in Q1 2023 and held it in 10 quarters. The position peaked at $3.83M in Q2 2023. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Jacobs Levy Equity Management reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 142,641 Y-mAbs Therapeutics shares in Q3 2025, an estimated $643K.
  • Jacobs Levy Equity Management first reported a position in Y-mAbs Therapeutics in Q1 2023 and held it in 10 quarters.
  • Jacobs Levy Equity Management's Y-mAbs Therapeutics position peaked at $3.83M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.